Lisocabtagene maraleucel
- Generic Name
- Lisocabtagene maraleucel
- Brand Names
- Breyanzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 7K2YOJ14X0
- Background
Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to brexucabtagene autoleucel and axicabtagene ciloleucel. Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4.
...
- Indication
Lisocabtagene maraleucel is indicated to treat adults with relapsed or refractory large B-cell lymphoma after β₯2 systemic therapies, diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma.
- Associated Conditions
- Grade 3b Follicular Lymphoma, High-grade B Cell Lymphoma (HGBCL), Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Associated Therapies
- -
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT06357754
- Locations
- πΊπΈ
University Of Wisconsin, Madison, Wisconsin, United States
π©πͺUniversitaetsklinikum Essen (AoR), Essen, Germany
π―π΅Kumamoto University, Kumamoto-city, Kumamoto, Japan
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Biological: Axicabtagene CiloleucelProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideBiological: MosunetuzumabOther: Patient ObservationDrug: FludarabineDrug: Polatuzumab VedotinBiological: Lisocabtagene MaraleucelProcedure: Positron Emission TomographyBiological: Tisagenlecleucel
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 396
- Registration Number
- NCT05633615
- Locations
- πΊπΈ
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
πΊπΈHighlands Oncology Group - Rogers, Rogers, Arkansas, United States
πΊπΈHighlands Oncology Group, Springdale, Arkansas, United States
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 33
- Registration Number
- NCT05621096
- Locations
- πΊπΈ
University of Nebraska Medical Center, Omaha, Nebraska, United States
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
- Conditions
- Refractory B-Cell Non-Hodgkin LymphomaRefractory Aggressive B-cell LymphomasAggressive B-cell NHLDe Novo or Transformed Indolent B-cell LymphomaHigh-Grade B-Cell Lymphoma, NosGrade 3b Follicular LymphomaT Cell/Histiocyte-rich Large B-cell LymphomaC-MYC/BCL6 Double-Hit High-Grade B-Cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)DLBCL, Nos Genetic Subtypes
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Patrick C. Johnson, MD
- Target Recruit Count
- 27
- Registration Number
- NCT05583149
- Locations
- πΊπΈ
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Refractory Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3b Follicular LymphomaRefractory Grade 3b Follicular LymphomaRefractory Primary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: Lisocabtagene MaraleucelDrug: Polymer-conjugated IL-15 Receptor Agonist NKTR-255Procedure: X-Ray ImagingProcedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Lumbar PunctureProcedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Biospecimen CollectionProcedure: Biopsy
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05359211
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 57
- Registration Number
- NCT05075603
- Locations
- πΊπΈ
Duke Cancer Institute, Durham, North Carolina, United States
πΊπΈCity of Hope, Duarte, California, United States
πΊπΈBarbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.